DESTINY Breast05 (GBG 103)
T-DXd vs. T-DM1 in high risk HER2-positive patients with residual invasive breast cancer following neoadjuvant therapy
(DESTINY-Breast05; NSABP B-60; GBG-103; SOLTI-2001.NCT04622319 )
Introduction
A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05)
Trial overview was presented at the GBG annual meeting 2021.See the video online or download the slides here:
-
TruDy/Destiny-B05
(807 KB)
TruDy/Destiny-B05 - Trastuzumab Deruxtecan beim HER2-positiven Mammakarzinom, Prof. Dr. Peter A. Fasching, Universitätsklinikum Erlangen.
News
Trials is open for recruting.
Documents
The following documents are available as download:
-
MammaMia_Sonderdruck_Destiny-B05.pdf
(145 KB)
-
Flyer_Studienzentren.pdf
(804 KB)
Berechtigte und angemeldete Benutzer können hier weitere interne Dokumente abrufen. Haben Sie bereits einen Login? Dann melden Sie sich hier an.
Contact
dstny-b05gbgd
Fax: +496102 / 7480-440
Project Management
Viktoria Tierbach
Dr. Ioannis Gkantiragas